{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T05:10:36Z","timestamp":1760505036829,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:27:51Z","timestamp":1752593271000},"page":"885-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line Therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"Jennifer","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.hoc.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-16-0955","article-title":"Venetoclax in patients with previously treated chronic lymphocytic leukemia","volume":"23","author":"Roberts","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.007_bib2","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson","year":"1996","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.007_bib5","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.hoc.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.007_bib7","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evidence"},{"issue":"22","key":"10.1016\/j.hoc.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.hoc.2025.05.007_bib9","first-page":"3853","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Orthod"},{"issue":"14","key":"10.1016\/j.hoc.2025.05.007_bib10","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase II CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2024-200632","article-title":"CRISTALLO: results from a phase III trial of venetoclax-obinutuzumab versus fludarabine, cyclophosphamide and rituximab or bendamustine-rituximab in patients with untreated chronic lymphocytic leukemia without del(17p) or TP53 mutations","volume":"144","author":"Sharman","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.007_bib14","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.007_bib15","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib\u2013venetoclax versus chlorambucil\u2013obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2024-203269","article-title":"First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): glow study 64-month follow-up (FU) and adverse event (AE)-Free progression-free survival (PFS) analysis","volume":"144","author":"Niemann","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.05.007_bib17","first-page":"7009","article-title":"Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): up to 5.5 years of follow-up in the phase 2 CAPTIVATE study","volume":"42","author":"Wierda","year":"2024","journal-title":"J Clin Orthod"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib18","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2024-200936","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic lymphocytic leukemia therapy guided by measurable residual disease","volume":"390","author":"Munir","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.007_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.007_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator\u2019s choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.007_bib23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2025.05.007_bib24","article-title":"Zanubrutinib and venetoclax for treatment-naive chronic lymphocytic leukemia\/small lymphocytic lymphoma with and without del (17p)\/TP53 mutation: SEQUOIA arm D results","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib25","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1182\/blood-2023-174751","article-title":"Tailor: interventional study evaluating physician\u2019s choice of ibrutinib monotherapy or ibrutinib-venetoclax combination using dose modifications and alternate dosing approaches in patients with untreated chronic lymphocytic leukemia","volume":"142","author":"Sharman","year":"2023","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.hoc.2025.05.007_bib26","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.2217\/fon-2022-0456","article-title":"MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"18","author":"Ryan","year":"2022","journal-title":"Future Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2024-211454","article-title":"Combined pirtobrutinib, venetoclax, and obinutuzumab as first-line treatment of patients with chronic lymphocytic leukemia (CLL)","volume":"144","author":"Jain","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.05.007_bib28","first-page":"TPS7087","article-title":"CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL","volume":"42","author":"Shadman","year":"2024","journal-title":"J Clin Orthod"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.007_bib29","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","article-title":"Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2","volume":"67","author":"Guo","year":"2024","journal-title":"J Med Chem"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.007_bib30","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1182\/blood-2023-183071","article-title":"Updated efficacy and safety results of lisaftoclax (APG-2575) in patients (pts) with heavily pretreated chronic lymphocytic leukemia (CLL): pooled analyses of two clinical trials","volume":"142","author":"Zhou","year":"2023","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000796?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000796?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:51:02Z","timestamp":1760503862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000796"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line Therapy","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}